الفهرس 
AIM OF THE WORKOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
This study is to evaluate the level of cystatin C in T2DM patients with obesity.
To elucidate our results. This is a cross-sectional and observational study designed to compare the level of cystatin C in obesity and T2DM. The study population consisted of 301 newly diagnosed patients with T2DM according to American Diabetes Association, attended to Internal Medicine department in Menoufia University hospital, 130 obese non diabetic patients and 130 healthy subjects of comparable age and sex as a control group during the period from November 2020 to December 2021.
Subjects included in this study were divided into two groups as follows:
group A: included 130 Nondiabetic obese patients.
group B: included 155 type 2 diabetic patients with obesity.
group C: included 146 type 2 diabetic patients with no obesity.
group D: included 130 healthy subjects of comparable age and sex as a control group (Nondiabetic non obese patients).
All patients were subjected to the following: Written or informed consent. Full medical history taking including: Age, sex, smoking, full history of diagnosed cirrhotic patients was screened. Information about alcohol intake, viral hepatitis C and B, family history of chronic liver diseases or other chronic illness was collected and history of blood or albumin transfusion. Laboratory Investigations including: CBC, ALT, AST, serum total direct bilirubin, ALP, serum albumin, PT, PTT, INR, serum urea and creatinine, Body Mass Index (Obesity BMI >30), HbA1c and serum Cystatin C using ELIZA.